The complete synthesis of favipiravir from 2-aminopyrazine
- 121 Downloads
Favipiravir was first synthesized from an inexpensive and commercially available starting material, 2-aminopyrazine. The preferred route embedded within Scheme 4 consisted of seven steps, and was highlighted by the novel and efficient synthesis of 3,6-dichloropyrazine-2-carbonitrile 8. This intermediate was prepared in four successive steps which were regioselective chlorination of the pyrazine ring, bromination, Pd-catalyzed cyanation, and Sandmeyer diazotization/chlorination. This protocol eliminated the hazardous POCl3 of previous synthetic methods and offered a better yield (48%) which was 1.3-fold higher than a recently published procedure. From intermediate 8, the subsequent nucleophilic fluorination, nitrile hydration and hydroxyl substitution efficiently afforded the target product. Another synthetic approach with the same starting material was also investigated to bypass the allergy-causing dichloro intermediate 8. However, the key step of monofluorination at the pyrazine C6 position of intermediate 19 or 22 was not achieved.
KeywordsFavipiravir 2-Aminopyrazine Fluorination Sandmeyer reaction
This work was supported by National Science Foundation for Young Scientists of China (Grant no. 21502209). The authors gratefully acknowledged Topharman Shanghai Co., Ltd for collaboration.
Compliance with ethical standards
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
- Bai CQ, Mu JS, Kargbo D, Song YB, Niu WK, Nie WM, Kanu A, Liu WW, Wang YP, Dafae F, Yan T, Hu Y, Deng YQ, Lu HJ, Yang F, Zhang XG, Sun Y, Cao YX, Su HX, Sun Y, Liu WS, Wang CY, Qian J, Liu L, Wang H, Tong YG, Liu ZY, Chen YS, Wang HQ, Kargbo B, Gao GF, Jiang JF (2016) Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705)-Sierra leone, 2014. Clin Infect Dis 6310:1288–1294. https://doi.org/10.1093/cid/ciw571 CrossRefGoogle Scholar
- Beldar SV, Jordis U (2009) Synthetic studies towards the antiviral pyrazine derivative T-705. Institute of Applied Synthetic Chemistry, Vienna University of Technology, Vienna, p 13Google Scholar
- Cai L, Pike V W, Innis R B (2007) (Aminophenyl)imidazo[1,2-a]pyridine derivatives useful as beta-amyloid PET imaging agents and their preparation. WO2007124345A2 (issued November 1, 2007)Google Scholar
- Furuta Y, Egawa H (2000) Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing both. European Patent Office WO, 00/10569 (issued March 2, 2000)Google Scholar
- Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD (2009) T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antivir Res 823:95–102. https://doi.org/10.1016/j.antiviral.2009.02.198 CrossRefGoogle Scholar
- Hara T, Norimatsu N, Kurushima H, Kano T (2010) Method for producing dichloropyrazine derivative. European Patent Office WO2010087117 (issued August 2, 2012)Google Scholar
- Huchting J, Vanderlinden E, Winkler M, Nasser H, Naesens L, Meier C (2018) Prodrugs of the phosphoribosylated forms of hydroxypyrazinecarboxamide Pseudobase T-705 and its de-fluoro analogue T-1105 as potent influenza virus inhibitors. J Med Chem 61:6193–6210. https://doi.org/10.1021/acs.jmedchem.8b00617 CrossRefGoogle Scholar
- Jin Z, Tucker K, Lin X, Kao CC, Shaw K, Tan H, Symons J, Behera I, Rajwanshi VK, Dyatkina N, Wang G, Beigelman L, Deval J (2015) Biochemical evaluation of the inhibition properties of favipiravir and 2′-C-methyl-cytidine triphosphates against human and mouse norovirus RNA polymerases. Antimicrob Agents Chemother 5912:7504–7516. https://doi.org/10.1128/aac.01391-15 CrossRefGoogle Scholar
- Klejch T, Pohl R, Janeba Z, Sun M, Keough D, Guddat L, Hockova D (2018) Acyclic nucleoside phosphonates with unnatural nucleobases, favipiravir and allopurinol, designed as potential inhibitors of the human and Plasmodium falciparum 6-oxopurine phosphoribosyltransferases. Tetrahedron 74:5886–5897. https://doi.org/10.1016/j.tet.2018.08.014 CrossRefGoogle Scholar
- Li M (2017) Synthetic method of favipiravir. State Intellectual Property Office of the P.R.C. CN107226794A (issued October 3, 2017)Google Scholar
- Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J (2013) Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol Pharmacol 844:615–629. https://doi.org/10.1124/mol.113.087247 CrossRefGoogle Scholar
- Wang G, Wan J, Hu Y, Wu X, Prhavc M, Dyatkina N, Rajwanshi VK, Smith DB, Jekle A, Kinkade A, Symons JA, Jin Z, Deval J, Zhang Q, Tam Y, Chanda S, Blatt L, Beigelman L (2016) Synthesis and anti-influenza activity of pyridine, pyridazine, and pyrimidine C-nucleosides as favipiravir (T-705) analogues. J Med Chem 5910:4611–4624. https://doi.org/10.1021/acs.jmedchem.5b01933 CrossRefGoogle Scholar